How International Cannabis Trade Actually Works

Photo by Bilal Ahmed via Pexels.

Ship a container of coffee from Colombia to Germany and the paperwork is a customs declaration and a certificate of origin. Ship medical cannabis flower along the same route and you need a matched pair of government-issued permits, a facility that has passed a pharmaceutical inspection most cultivators will never clear, and a regulator on each end willing to sign off on the specific shipment. There is no cannabis equivalent of a WTO schedule, no regional free-trade chapter, nothing that functions like the agreements that move grain, steel, or wine across borders on predictable terms. Every legal shipment moves because two governments agreed to it, one shipment at a time.

The reason traces back further than most people assume -- not to any recent drug policy fight, but to a treaty signed in 1961, decades before Canada or Uruguay or Germany had anything resembling a legal cannabis market. That treaty still sets the terms every exporter operates under today. And yet, within that narrow permit-by-permit system, a real trade has emerged: several hundred tonnes a year moving between a small set of countries that have figured out how to clear the bureaucratic bar. This piece walks through how that system actually works -- the treaty, the certification standard that decides who gets to play, and the countries currently doing real volume.

The 1961 Treaty Still Runs the Show

Photo by Ylanite Koppens via Pexels.

The document that governs almost every legal cannabis shipment on earth predates modern legalization by half a century. The UN Single Convention on Narcotic Drugs, adopted in 1961, classifies cannabis alongside opium and coca as a controlled substance, and Article 31 spells out exactly how it can cross a border: with a government-issued export authorization matched to a government-issued import authorization, both routed through each country's designated "competent authority." No permit pair, no shipment -- full stop, regardless of what either country's domestic law says about legality.

That structure hasn't budged much despite years of pressure. The Commission on Narcotic Drugs, the UN body that oversees the treaty, has repeatedly considered and voted down proposals that would have loosened the trade provisions for cannabis specifically. Member states reclassified cannabis's medical risk profile within the treaty's scheduling annexes back in 2020, but that was a rescheduling of harm categories, not a rewrite of the export permit mechanics. Article 31 still applies exactly as written.

What this means in practice is that there's no cannabis version of a WTO agreement, no NAFTA-style chapter, no regional bloc that treats cannabis the way the EU treats, say, dairy or automobiles. A grower in Ontario doesn't get automatic access to German patients just because both countries have legalized medical cannabis domestically. Each shipment requires a bespoke bilateral clearance -- Canada's competent authority (Health Canada) issuing an export permit, Germany's counterpart (BfArM) issuing a matching import permit, and both documents having to reconcile on quantity, product form, and destination facility before customs will release anything.

That's the structural reason a fully-legal-at-home cannabis industry still can't export like a coffee cooperative or a vineyard. Legality inside your own borders buys you nothing internationally. The treaty doesn't care whether Canada or Thailand or Colombia has legalized cannabis for medical or even recreational use -- it cares whether the two governments involved in a specific shipment have each done their part of the paperwork. That's the ceiling every exporter in this industry is building underneath.

EU-GMP Certification Became the De Facto Passport

Photo by Sulyok Img via Unsplash.

If the 1961 treaty decides whether a shipment is legally possible, EU-GMP certification decides whether it's commercially viable. Good Manufacturing Practice standards were never written with cannabis in mind -- they're the same pharmaceutical quality framework the EU uses for insulin and antibiotics -- but when Canadian companies started trying to sell dried flower and extracts into European pharmacies around 2017-2018, EU regulators simply applied the existing pharma rulebook. No GMP certificate, no shelf space in a German or Dutch pharmacy.

That single requirement has quietly become the real global passport for this industry. It's not written into any cannabis-specific treaty; it's just that the EU pharmaceutical supply chain, which is where almost all serious legal demand currently sits, won't move product without it. Facilities holding EU-GMP certification for cannabis now operate in a short list of places: Canada, Portugal, the Netherlands, Colombia, Australia, Uruguay, and Germany itself. That's essentially the entire list of countries capable of exporting into the EU's medical channel at any real volume.

Everyone else is locked out, and domestic legal status doesn't change that. A country can legalize cannabis outright for its own citizens and still have zero export capacity into Germany, France, or the UK's medical channel if none of its facilities have cleared a GMP inspection. The inspections themselves are rigorous and expensive -- covering everything from cultivation environment controls to extraction validation to batch record-keeping -- and they take most operators years and real capital to pass, if they pass at all.

What actually enables the cross-border movement, mechanically, are Mutual Recognition Agreements between regulatory bodies on pharmaceutical manufacturing standards -- not any cannabis-specific accord. The EU recognizes Health Canada's GMP inspections as equivalent to its own under a broader pharma MRA framework, which is why a Canadian-grown, GMP-certified product can land in a German pharmacy without Germany re-inspecting the Canadian facility from scratch. Strip away the GMP layer and none of this works, no matter what the treaty allows on paper.

Canada's Export Boom and the Germany Pipeline

Canada is the country that's actually converted this permit-and-certification system into scale, and the 2025 numbers show how far it's stretched. Canadian medical cannabis exports topped 275 tonnes in 2025, up 143% year-on-year -- a jump that's less about new demand appearing out of nowhere and more about a supply chain that finally has enough GMP-certified capacity to fill it.

Germany is where almost all of that growth is landing. Canadian shipments into Germany surged 298% year-on-year, and data from BfArM, Germany's federal drug regulator, shows Canada shipped 93 tonnes directly into the country in 2025 -- up 181% from the year before, and enough to account for roughly half of everything Germany imported. That's a striking concentration: one exporting country supplying half the import needs of what's now Europe's largest medical cannabis market.

The other shift worth flagging is the routing. For years, Portugal functioned as the European processing and re-export hub -- Canadian product would land there, get processed or repackaged at a GMP-certified Portuguese facility, and move onward into Germany and other EU markets from there. Increasingly, Canadian exporters are skipping that step and shipping direct to Germany. It's a sign the direct Canada-to-Germany permit relationship has matured enough that firms don't need the Portuguese intermediary layer to move volume efficiently anymore.

None of this happens without the demand side, and that's squarely a German story. Germany's Medical Cannabis Act, which passed in February 2024, restructured how German patients access cannabis and effectively turned the country into the continent's biggest import destination almost overnight. Canada had the GMP-certified production capacity sitting ready when that demand opened up, which is a large part of why the export numbers moved as fast as they did. It's a clean example of how, in this industry, one country's domestic law change can instantly become another country's export boom.

Germany Is Tightening the Rules It Just Opened

Photo by Mustafa Gökhan Ertin via Pexels.

Germany opened the tap in February 2024, and it's now moving to partially close it -- not by reversing legalization, but by clamping down on how patients get access to imported product. On July 14, 2025, Health Minister Nina Warken published a draft regulation proposing mandatory in-person medical consultations before a cannabis prescription can be issued, alongside an outright ban on mail-order cannabis sales, the channel through which a large share of imported product has been reaching German patients.

The draft moved through the German policymaking pipeline with unusual speed for this kind of measure. The Cabinet approved it on October 8, 2025. The Bundestag held its first reading on December 18, 2025, and a full vote is expected around April 2026. That timeline puts a hard, dated checkpoint on the calendar for anyone watching this supply chain -- this isn't a vague regulatory possibility, it's a bill on a track with a known destination.

If the mail-order ban passes as drafted, it changes the plumbing of how German patients actually receive imported cannabis, not just the paperwork behind it. Mail-order pharmacy models have been a major access point precisely because they scale efficiently against high import volumes; forcing patients into in-person consultations and away from mail delivery restructures demand at the retail end in a way that inevitably works its way back up the chain to import volumes, and from there to Canadian export scheduling.

The broader lesson here is one that gets lost in a lot of industry coverage: the treaty and the GMP certification determine who's allowed to trade, but a single importing country's domestic access rules determine how much actually gets bought and shipped in a given year. Germany didn't touch its import permit system or its GMP requirements with this draft -- it touched how its own patients buy the product once it's already inside the country. That's proven to be enough, on its own, to threaten to swing the numbers on the other side of the Atlantic.

The US Rescheduling Mirage

Photo by SHOX ART via Pexels.

US rescheduling has generated more headlines than any other cannabis policy story of the past two years, and it's worth being precise about what it actually changed for trade, which is close to nothing. On April 22, 2026, Acting Attorney General Todd Blanche signed the final order moving FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III, acting on the executive order Trump signed December 18, 2025. That's a real and significant domestic regulatory shift. It is not a trade opening.

The order itself specifically amends DEA regulations to require import and export permits for Schedule III marijuana -- mirroring the same permit structure that already applied under Schedule I and Schedule II. In other words, the DEA rewrote the rule to make sure rescheduling didn't accidentally create a looser trade regime, because a looser regime would put the US out of step with Article 31 of the Single Convention. The US stays bound by the same permit-matching mechanics as everyone else; it just moved which schedule domestically triggers them.

A separate and more consequential process is still unresolved: a DEA hearing on full rescheduling began June 29, 2026, targeted to wrap by July 15, 2026. The optics aren't promising for advocates of a bigger shift -- all seven hearing participants the DEA selected on June 18, 2026 are reportedly opposed to rescheduling going any further. That hearing outcome, not the April order, is the thing likely to actually move policy in either direction.

On the tariff side, CUSMA -- the US-Mexico-Canada trade agreement -- offers a narrow illustration of how limited even friendly trade frameworks are here. Tetrahydrocannabinols, THC specifically, get zero tariffs moving between the US and Canada under CUSMA. That's a single carved-out chemical category, not a cannabis trade chapter, and it says a lot about how cautiously trade negotiators have handled this plant even between two countries with extensive legalization on both sides of the border.

The New Undercutters: Colombia, Thailand, Macedonia, South Africa

Photo by Matteo Paganelli via Unsplash.

Canada built its export position early and has the tonnage to show for it, but it's no longer the only serious option on the EU-GMP side of the ledger. StratCann's 2025 data flags Colombia, Thailand, North Macedonia, and South Africa as the fastest-rising exporters, and the reason is straightforward: once a facility clears EU-GMP inspection, the treaty and certification barriers that keep most countries out stop mattering, and what's left is ordinary price competition.

These four countries are undercutting established suppliers -- Canada, the Netherlands, Portugal -- on price for GMP-certified flower and extract, and the gap isn't marginal. Colombia's cultivation costs benefit from year-round growing conditions and lower labor costs than North American operations. Thailand and North Macedonia offer similar labor-cost advantages relative to Canada and Western Europe, paired with governments that have moved deliberately to build out GMP-compliant infrastructure specifically to capture EU pharmaceutical demand. South Africa is following a comparable playbook, leaning on established agricultural infrastructure and lower input costs to compete on landed price into Europe.

None of these countries currently match Canada's scale -- nobody is shipping 93 tonnes into Germany alone the way Canada did in 2025 -- but scale isn't the only lever in a market where buyers are pharmaceutical distributors comparing landed cost per gram across certified suppliers. A German or Dutch pharmaceutical importer sourcing GMP-certified extract doesn't need one dominant supplier; it needs the cheapest compliant one available for a given order, and that's exactly the opening lower-cost producers are stepping into.

The direction of travel is toward a wider field, not a narrower one. As more facilities in Colombia, Thailand, North Macedonia, and South Africa clear GMP inspection, the early-mover advantage that let Canada, the Netherlands, and Portugal dominate the first wave of this trade erodes a little more each year. The treaty framework hasn't changed and isn't likely to. What's changing is how many countries have figured out how to operate profitably within it.

Step back from the individual data points and the shape of this industry becomes clear: the binding constraint on cannabis trade has never really been consumer demand, and it's not even domestic law anymore in most of the relevant countries. It's a treaty written in 1961 and a pharmaceutical certification regime designed for insulin plants, not cannabis farms. Everything else -- Canada's export boom, Germany's import surge, Colombia's price undercutting -- is downstream of whether a country can satisfy those two gatekeepers.

Two dates are worth putting on a calendar rather than treating as background noise. Germany's Bundestag is expected to vote on the mail-order cannabis ban around April 2026, and that vote will directly affect import volumes in the country currently absorbing roughly half of Canada's export tonnage. The DEA's rescheduling hearing is targeted to conclude by July 15, 2026, and given that all seven selected participants are reportedly opposed to further rescheduling, it's a reasonable bet that headline stays a domestic story rather than a trade one. Both outcomes will move real tonnage. Most rescheduling headlines, by contrast, won't move a single shipment.

The longer trend is a diversifying export map. Canada got there first and still has scale nobody else matches, but Colombia, Thailand, North Macedonia, and South Africa are proving that GMP certification is a bar any well-capitalized operation can eventually clear, treaty or no treaty. Expect that list of certified exporting countries to keep growing over the next few years -- not because the Single Convention loosens, but because more governments have learned exactly how to work within it.